India has 3 Covid-19 vaccines in different phases of clinical testing: ICMR

Rajesh Bhushan, Secretary, Health Ministry said the actual caseload of Covid-19 in the country today is 5,86,298 as more than 1.2 million people have already recovered

A healthcare worker wearing PPE kit interacts with  children at CWG COVID Care Centre,  in New Delhi on Saturday
A healthcare worker wearing PPE kit interacts with children at CWG COVID Care Centre, in New Delhi on Saturday
Press Trust of India New Delhi
2 min read Last Updated : Aug 04 2020 | 6:30 PM IST
At present country has three Indian Covid-19 vaccines which are in different phases of clinical testing, said Indian Council of Medical Research (ICMR) on Tuesday.

"At the present moment, we have three Indian vaccines which are in different phases of clinical testing. The 2 vaccines- Bharat Biotech vaccine and DNA vaccine of Zydus Cadila have completed phase 1 and will begin phase 2 while third is Oxford vaccine," said Dr Balram Bhargava, DG, ICMR while addressing a press conference here.

"Oxford vaccine, being manufactured by Serum Institute of India (SII) got approval for phase 2 and 3 clinical trials, which are starting within a week at 17 sites," he added.

Dr Bhargava, however, said that social distancing and proper hygiene are the best "vaccine" available now and even after.


"Physical Distancing, wearing a mask, proper hand hygiene are the best vaccine available at the moment and even after. We will have to continue with these measures," he said.

Rajesh Bhushan, Secretary, Health Ministry said the actual caseload of Covid-19 in the country today is 5,86,298 as more than 1.2 million people have already recovered.

India witnessed a single-day spike of 52,050 Covid-19 cases as the total count of cases in the country reached 18,55,746 on Tuesday.

The number of cured/discharged/migrated patients stands at 12,30,510 and 38,938 persons have died, the Health Ministry added.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Coronavirushealth care sectorCOVID-19

Next Story